OP31.02: Single nucleotide polymorphism in pre‐eclampsia prediction

prenatal clinic setting. Maternal levels of PAPP-A were measured at the time of the first prenatal visit (9 to 13+6 weeks) as part of the combined ultrasound and biochemical screening study. Low PAPP-A was defined as the lowest 5% of values for gestational age ( 1.9 MoM). Intrauterine growth restriction was defined as birth-weight ≤3th centile according to our local customized charts. The risk of IUGR in women with a low PAPP-A and normal AFP was compared with a control group with low PAPPA and high AFP. No results were reported to either the obstetrician or patient. Results: A total of 5617 pregnant women were attended for prenatal care in our institution between January 2010 and December 2011. Of the 301 patients with a PAPP-A < 0.4 MoM, 141 had a determination of AFP done between 15 and 18 weeks and perinatal outcome is known for 96 of these patients. Women with a low PAPP-A were not more likely to have elevated levels of AFP. Only 4 patients (4.2%) had a low PAPP-A and high AFP. We had 6 cases of IUGR (6%): 3 cases (3.2%) in the group of low PAPP-A and normal AFP and 3 cases (75%) in the group of low PAPP-A and high AFP. The odds ratio for delivering a baby with IUGR for women with low PAPP-A and high AFP was 89 (95% confidence interval [CI] 7–1127). Conclusions: Although the small numbers of the study, this preliminary data suggest that low maternal levels of PAPP-A between 8 and 13+6 weeks and high levels of AFP between 15 and 18 weeks are highly associated with IUGR.